SNN Smith and Nephew Plc New

Latest expansion to the CORI◊ Surgical System portfolio provides a personalized solution for patients and surgeons

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces its CORIOGRAPH Pre-Op Planning and Modeling Services is now cleared for total hip arthroplasty (THA) by the United States Food and Drug Administration. Exclusively for users of the CORI Surgical System, this innovative planning software allows for use of either X-rays or CT scans for planning and modeling, enabling surgeons to make a patient-specific plan for the best possible outcome.

The first procedures using CORIOGRAPH Pre-Op Planning and Modeling Services for Hip with RI.HIP solutions were recently completed by Dr. George Haidukewych, Surgeon in Chief and Academic Chairman at Orlando Health Jewett Orthopedic Institute in Orlando, FL. He stated, “The plan was extremely accurate and provided an opportunity to trial different offsets and combinations prior to surgery. This was invaluable in saving time and optimizing component position and sizing. CT based templating with patient specific impingement modeling is clearly superior to traditional methods of digital templating. It allows for personalization of the surgery to the patient’s specific needs of activities of daily living.”

The CORI Surgical System offers proprietary tools and software across the full suite of procedure solutions to deliver a platform that is flexible and scalable across knee and hip joint arthroplasty indications. Built on 15+ years of clinical expertise and over 350,000 image-based hip and knee surgery plans, CORIOGRAPH Pre-Op Planning and Modeling Services for Hip is designed to optimize implant planning and personalization, including:

• Advanced modeling capabilities that utilize patient specific spinopelvic classification and pelvic tilt go beyond the mechanics of simple range-of-motion to simulate activities of daily living that help surgeons make decisions on optimal implant placement.
• Image-agnostic planning capabilities with 2D and/or 3D images to help personalize the end-to-end care specifically to the patient need.
• Can be used across the entire spectrum of Smith+Nephew hip implant solutions and technologies.
• CORIOGRAPH Pre-Op Planning and Modeling Services combined with RI.HIP solutions and the recently launched CATALYSTEM◊ Primary Hip System, offer a complete solution for primary total hip arthroplasty.

“With the addition of Hip pre-op planning to CORIOGRAPH services, we are now truly personalizing surgery for hip and knee for each patients’ specific needs,” said Craig Gaffin, President of Global Orthopaedics at Smith+Nephew. “I can speak as the business leader and a patient here, as my hip was the first one to be planned with CORIOGRAPH services for Hip. Through the planning process, my surgeon was able to tell what kind of activities I can expect to perform after the surgery based on simulated models of my hip bones.”

To learn more about CORIOGRAPH Pre-Op Planning and Modeling Services and the CORI Surgical System, please visit https://www.smith-nephew.com/en-us/health-care-professionals/products/orthopaedics/coriograph.

- ends –

Media Enquiries

Dave Snyder          +1 (978) 749-1440 

Smith+Nephew      david.snyder@smith-nephew.com

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global business units of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.5 billion in 2023. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on X, LinkedIn, Instagram or Facebook.

This document is provided for informational purposes and is not intended to serve as medical advice. It is the responsibility of healthcare professionals to determine and utilise the appropriate products and techniques according to their own clinical judgment for each of their patients. The testimonials set out in this document represent the individual's opinions, findings, beliefs, and/or experiences. Individual results will vary. To review the information needed to understand and use CORIOGRAPH safely and effectively, including indications for use, contraindications, precautions, and warnings, please consult the applicable Instructions for Use (IFU) prior to use. Products featured may not be available in individual markets due to regulatory and/or medical practices. Please contact your Smith+Nephew representative if you have questions about availability of Smith+Nephew products in your area.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading profit margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: conflicts in Europe and the Middle East, economic and financial conditions in the markets we serve, especially those affecting healthcare providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal and financial compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and disposals, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; relationships with healthcare professionals; reliance on information technology and cybersecurity; disruptions due to natural disasters, weather and climate change related events; changes in customer and other stakeholder sustainability expectations; changes in taxation regulations; effects of foreign exchange volatility; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, which is available on the SEC’s website at www. sec.gov, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered in US Patent and Trademark Office.

Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Dec 2024 to Jan 2025

Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Jan 2024 to Jan 2025